Clinical Trials Directory

Trials / Completed

CompletedNCT06093009

The Significance of Postoperative Muscle Wasting in Pancreatic Cancer

National Cheng Kung University Hospital

Status
Completed
Phase
Study type
Observational
Enrollment
208 (actual)
Sponsor
National Cheng-Kung University Hospital · Academic / Other
Sex
All
Age
20 Years – 120 Years
Healthy volunteers

Summary

To assess the impact of preoperative sarcopenia and postoperative skeletal muscle wasting on the outcomes of patients with resectable pancreatic cancer who underwent pancreatectomy.

Detailed description

Previous studies have revealed that sarcopenia, defined as generalized loss of skeletal muscle mass, is a poor prognostic factor following surgery. However, research focusing on postoperative muscle wasting and its influence on the prognosis of resectable pancreatic cancer (PC) is limited. Investigators retrospectively reviewed 208 patients who underwent pancreatectomy for PC at the National Cheng Kung University Hospital (NCKUH) between June 2002 and April 2020. Clinical information regarding patient characteristics, pathological parameters, and biochemical features was collected from all patients using electronic medical records (EMRs) under an IRB-approved protocol (B-ER-110-420) at NCKUH. Preoperative psoas major area and the degree of muscle reduction at 3 months postoperatively were calculated using computed tomography to define sarcopenia and drastic muscle wasting. Patients were assigned to two groups based on sarcopenia or drastic muscle wasting, and compared for postoperative morbidity, disease free survival (DFS), and overall survival (OS).

Conditions

Interventions

TypeNameDescription
PROCEDUREpancreatectomy

Timeline

Start date
2002-06-01
Primary completion
2020-04-01
Completion
2023-06-01
First posted
2023-10-23
Last updated
2023-10-24

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT06093009. Inclusion in this directory is not an endorsement.